Erytech Pharma S.A.: ERYTECH to Participate in the Upcoming April Investor Conferences

ERYTECH to Participate in
theUpcomingAprilInvestor Conferences

---

Cambridge, MA (U.S.) and Lyon (France), March 28, 2022- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced their participation in upcoming investor conferences and invites investors to participate in one-on-one meetings:

Investor Access Event

Link to the event

• Date: Monday, April 4^th and Tuesday, April 5^th
• Place: Paris (France)
• Participant: Eric SOYER (CFO-COO)
  
  

Kempen 14th Life Sciences Conference

Link to the event

• Date: Thursday, April 21^st
• Place: Amsterdam (Netherlands)
• Participants: Gil BEYEN (CEO) and Eric SOYER (CFO-COO)
  
  

If you are interested in arranging a one-on-one meeting, please contact your conference representative.

About ERYTECH and eryaspase (GRASPA)

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH's primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company's lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells' altered asparagine and glutamine metabolism. The proof of concept of eryaspase as a cancer metabolism agent was established in different trials in acute lymphoblastic leukemia (ALL) and pancreatic cancer. An investigator sponsored Phase 2 trial (IST) evaluating the use of eryaspase in ALL patients who developed hypersensitivity reactions to pegylated asparaginase recently reported positive results, based on which the Company intends to request approval in the United States and potentially other territories. The Company is also pursuing a Phase 1 investigator-sponsored clinical trial in first-line pancreatic cancer.

Eryaspase received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer and treatment of acute lymphoblastic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase. The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

For more information, please visit www.erytech.com

CONTACTS

ERYTECH Eric Soyer CFO & COO	NewCap Mathilde Bohin / Louis-Victor Delouvrier Investor relations Nicolas Merigeau Media relations
[phone] [e-mail] (mailto:[e-mail])	[phone] [e-mail] (mailto:[e-mail])

Attachment

• 220328_ERYTECH_PR_APR 2022 Investor Conf_EN_vf-2 (https://ml-eu.globenewswire.com/Resource/Download/9f003e0f-2e06-44ad-a767-eccd9c4da053)